Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cediranib in Metastatic or Recurrent Renal Cell Carcinoma
NCT00423332Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Jan 2007
- Primary completion
- Mar 2008
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in renal cell carcinoma (RCC) comparing Cediranib Placebo with Cediranib (2 arms). Primary endpoint: Percentage Change From Baseline in Tumour Size at 12 Weeks. Started Jan 2007; status: completed.
02
Drugs
cediranib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00423332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00423332.